| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.54.5.1050 |
| P698 | PubMed publication ID | 10720273 |
| P50 | author | John T. O'Brien | Q37830687 |
| Clive Ballard | Q40279915 | ||
| Ian G. McKeith | Q51844656 | ||
| P2093 | author name string | P Thompson | |
| P G Ince | |||
| A F Fairbairn | |||
| R Barber | |||
| R H Perry | |||
| E K Perry | |||
| E Jaros | |||
| A Swann | |||
| K Lowery | |||
| D Neill | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dementia | Q83030 |
| P304 | page(s) | 1050-1058 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies | |
| P478 | volume | 54 |
| Q39615532 | (123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A compa |
| Q36917620 | A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia |
| Q45191523 | Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions |
| Q48616513 | Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology |
| Q43733467 | Adverse reactions to rivastigmine in three cases of dementia |
| Q33340612 | Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia |
| Q37106942 | Alzheimer's and non-alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies |
| Q38853776 | Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia |
| Q43738764 | Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation |
| Q48240618 | An advance in molecular imaging of dementias |
| Q36633738 | An individualized approach to treatment for alzheimer's disease, pick's disease, and other dementias |
| Q35484548 | Anosmia is very common in the Lewy body variant of Alzheimer's disease |
| Q35007862 | Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography |
| Q34581052 | Association between male gender and cortical Lewy body pathology in large autopsy series |
| Q33896664 | Biomarkers for cognitive impairment in Parkinson disease |
| Q92015050 | Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension |
| Q36395714 | Brain pathologies in extreme old age. |
| Q47344957 | Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically? |
| Q46569969 | Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life |
| Q33151494 | Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. |
| Q35194993 | Cerebral correlates of psychotic syndromes in neurodegenerative diseases |
| Q53454566 | Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. |
| Q34248241 | Cerebrospinal fluid biomarkers for dementia with lewy bodies |
| Q92451580 | Changes in gray matter volume and functional connectivity in dementia with Lewy bodies compared to Alzheimer's disease and normal aging: implications for fluctuations |
| Q48311450 | Clinical and neuropsychological features associated with structural imaging patterns in patients with mild cognitive impairment |
| Q21710734 | Clinical differentiation of parkinsonian syndromes: Prognostic and therapeutic relevance |
| Q49962915 | Clinical prevalence of Lewy body dementia. |
| Q35106476 | Clinicians' ability to diagnose dementia with Lewy bodies is not affected by β-amyloid load |
| Q40069625 | Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010. |
| Q37860194 | Clinicopathological correlates of behavioral and psychological symptoms of dementia |
| Q47819636 | Cognitive impairment and Charles Bonnet syndrome: a prospective study. |
| Q38410806 | Comparative analysis of cognitive impairments in lewy body dementia and Alzheimer's disease. |
| Q46836076 | Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease |
| Q35120662 | Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment |
| Q37078913 | Comparison of clinical manifestations in Alzheimer disease and dementia with Lewy bodies |
| Q41317541 | Comprehensive treatment of dementia with Lewy bodies |
| Q47748535 | Correlation between clinical symptoms and striatal DAT uptake in patients with DLB. |
| Q35659990 | Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A Comparison of Prodromal and Dementia Stages. |
| Q74082348 | Current awareness in geriatric psychiatry |
| Q61903306 | Current perspectives in dementia with Lewy bodies |
| Q74089880 | Definition of 'neuroleptic sensitivity' |
| Q33164331 | Delirium and dementia with Lewy bodies: distinct diagnoses or part of the same spectrum? |
| Q34811582 | Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles |
| Q57306397 | Dementia with Lewy bodies |
| Q74595912 | Dementia with Lewy bodies |
| Q79328891 | Dementia with Lewy bodies |
| Q80690619 | Dementia with Lewy bodies |
| Q35474145 | Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older |
| Q39703602 | Dementia with Lewy bodies is associated with higher scores on the Geriatric Depression Scale than is Alzheimer's disease |
| Q35573865 | Dementia with Lewy bodies. Review of diagnosis and pharmacologic management |
| Q36226812 | Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. |
| Q35029466 | Dementia with Lewy bodies: clinical characteristics and diagnostic criteria. |
| Q30667144 | Dementia with Lewy bodies: diagnosis and management |
| Q35029472 | Dementia with Lewy bodies: neuropathology |
| Q36832420 | Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice |
| Q36074760 | Diagnosis of dementia with Lewy bodies in clinical practice: a literature review |
| Q35789236 | Diagnosis of dementia with Lewy bodies: diagnostic performance of combined ¹²³I-IMP brain perfusion SPECT and ¹²³I-MIBG myocardial scintigraphy |
| Q35203115 | Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study |
| Q52564924 | Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. |
| Q48964060 | Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer's disease |
| Q43911586 | Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease |
| Q34636958 | Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography |
| Q35468295 | Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand |
| Q53269086 | Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT. |
| Q46122745 | Distinct cognitive phenotypes in Alzheimer's disease in older people |
| Q53839330 | Does cognitive profile distinguish Lewy body disease from Alzheimer's disease in the early stages? |
| Q37624612 | Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies |
| Q64081732 | Dynamic functional connectivity changes in dementia with Lewy bodies and Alzheimer's disease |
| Q30533941 | Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies |
| Q35479873 | Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct |
| Q79964392 | Fluctuations in cognitive function in dementia with Lewy bodies |
| Q46836071 | From the heart to the brain via cardiac MIBG imaging |
| Q48264359 | Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. |
| Q37003575 | Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease |
| Q47940917 | Functional connectivity in dementia with Lewy bodies: A within- and between-network analysis. |
| Q37145718 | Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer's disease. |
| Q43965633 | Hallucinations in an elderly cancer patient: opioid neurotoxicity or dementia with Lewy bodies? |
| Q36142447 | Higher cortical deficits influence attentional processing in dementia with Lewy bodies, relative to patients with dementia of the Alzheimer's type and controls |
| Q30999035 | How to diagnose dementia with Lewy bodies: state of the art. |
| Q35692950 | Imaging Alzheimer's disease: clinical applications |
| Q33530076 | Imaging improves diagnosis of dementia with lewy bodies |
| Q38228098 | Imaging the role of amyloid in PD dementia and dementia with Lewy bodies |
| Q38079317 | Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies |
| Q33444673 | Incidence and prediction of falls in dementia: a prospective study in older people |
| Q35183572 | Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies |
| Q22252940 | Interface between tauopathies and synucleinopathies: A tale of two proteins |
| Q33879821 | Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials |
| Q22248003 | Language performance in Alzheimer's disease and mild cognitive impairment: A comparative review |
| Q34566561 | Lewy bodies and dementia |
| Q34044014 | Lewy body dementia: the caregiver experience of clinical care |
| Q35843937 | Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype |
| Q33846330 | Long-term cognitive outcome of Alzheimer's disease and dementia with Lewy bodies: dual disease is worse. |
| Q35074859 | Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies |
| Q36635473 | Management of Parkinson's disease dementia : practical considerations |
| Q36141850 | Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. |
| Q42792695 | Morphological Factor Estimation via High-Dimensional Reduction: Prediction of MCI Conversion to Probable AD. |
| Q36727465 | Morphometry of the human substantia nigra in ageing and Parkinson's disease |
| Q35785744 | Multimodality imaging characteristics of dementia with Lewy bodies |
| Q50199884 | Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism |
| Q52983240 | Neuroimaging for diagnosing dementia with Lewy bodies: What is the best neuroimaging technique in discriminating dementia with Lewy bodies from Alzheimer's disease? |
| Q30844900 | Neuroimaging in Alzheimer disease: an evidence-based review |
| Q30756562 | Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology |
| Q53373258 | Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies. |
| Q81462534 | Neurology training in the United Kingdom: a diagnostic analysis of over 5000 patients |
| Q74245351 | Neuropathological correlates to clinically defined dementia with Lewy bodies |
| Q35540178 | Neuropathological spectrum of synucleinopathies |
| Q49077076 | Neuropathology of dementia with Lewy bodies |
| Q36525764 | Non-motor aspects of Parkinson's disease. |
| Q38801645 | Onset Patterns and Initial Symptoms of Dementia with Lewy Bodies: Possible Pathophysiological Diversities Deduced from a SPECT Study |
| Q48567127 | Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification |
| Q50980479 | Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study. |
| Q34289458 | Pick body disease and Pick syndrome |
| Q48477277 | Pick's pathology in Parkinson's disease with dementia |
| Q38006466 | Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer's Disease - An Unexpected Finding? |
| Q36813196 | Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications |
| Q37498339 | Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection |
| Q48378397 | Predicting lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer's disease |
| Q33874572 | Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders |
| Q51953384 | Prevalence of dementia with Lewy bodies in an inpatient psychogeriatric population in Hong Kong Chinese. |
| Q51972716 | Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. |
| Q49353206 | Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies |
| Q39004255 | Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management. |
| Q44400998 | Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: A case series |
| Q50052758 | Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. |
| Q37363768 | Rates of cerebral atrophy differ in different degenerative pathologies |
| Q48167210 | Regional cerebral blood flow in Parkinson's disease with and without dementia |
| Q53345545 | Reimbursement of acetilcholinesterase inhibitors for Alzheimer's disease in Europe. |
| Q40630680 | Revisiting DLB Diagnosis: A Consideration of Prodromal DLB and of the Diagnostic Overlap With Alzheimer Disease |
| Q34640941 | Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases |
| Q35607217 | Role of dopamine transporter imaging in routine clinical practice |
| Q48240563 | Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study |
| Q34079598 | Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. |
| Q44918550 | Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease |
| Q90289934 | Structural Brain Correlates of Attention Dysfunction in Lewy Body Dementias and Alzheimer's Disease |
| Q48420549 | The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening |
| Q49189061 | The Cambridge Behavioural Inventory revised |
| Q34138207 | The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease |
| Q36015683 | The Pareidolia Test: A Simple Neuropsychological Test Measuring Visual Hallucination-Like Illusions |
| Q52019569 | The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. |
| Q50675339 | The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease |
| Q36772321 | Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors |
| Q37552865 | Treatment of dementia with lewy bodies |
| Q36373719 | Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease |
| Q24653609 | Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases |
| Q45987521 | Value of analyzing deep gray matter and occipital lobe perfusion to differentiate dementia with Lewy bodies from Alzheimer's disease. |
| Q35468591 | Visual association test to detect early dementia of the Alzheimer type |
| Q47887473 | Visuospatial impairment in dementia with Lewy bodies and Alzheimer's disease: a process analysis approach |
| Q38088747 | What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. |
| Q80428500 | Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexes |
| Q53385156 | [The current diagnostic approach for chronic progressive dementia]. |
| Q37699179 | fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies |
Search more.